Can objective endpoints be manipulated in unmasked trials?

Biometry Research Group, National Cancer Institute, Executive Plaza North, Suite 3131, 6130 Executive Boulevard, MSC 7354, Bethesda, MD, 20892-7354, U.S.A.. .
Statistics in Medicine (Impact Factor: 2.04). 12/2011; 30(30):3573-4; author reply 3575. DOI: 10.1002/sim.4312
Source: PubMed
  • [Show abstract] [Hide abstract]
    ABSTRACT: Regulatory guidance on the development of drugs has existed for well over half a century in some territories. As drug development grew to become global so was born the need for harmonization. Beginning in the 1990 s, the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) developed guidelines which were adopted by the Food and Drug Administration (FDA) in the U.S.A., the European Medicines Agency (EMA) in the European Union and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan. These guidelines are generally not disease specific. A visit to the web sites of any of the aforementioned Agencies or, for that matter other regulatory agencies outside of these, will witness a plethora of additional/separate guidances, some of which are disease specific. In addition to such written guidances, more specific advice (for example, on a drug development program at the end of Phase II) may be requested from the Regulator. Despite the harmonization efforts expressed through ICH, the actual advice given by different regulatory authorities in practical situations, however, may be inconsistent. This paper will describe a case of seeking advice on a Phase III programme from the FDA and the EMA, obtaining different opinions and developing an innovative solution to satisfy both Authorities without necessarily extending development time significantly. The case is chronic kidney disease; the issues concern study design (non-inferiority, margin, etc.); the solution required a non-traditional design and associated sample size considerations. We conclude with some general advice on 'talking to the regulator'. This work was originally presented as a Poster at the Statistical Methods in Biopharmacy, 6th International Meeting, Paris, 21-22 September 2009.
    Statistics in Medicine 06/2011; 30(13):1628-35. DOI:10.1002/sim.4158 · 2.04 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Many clinical trials of uncommon diseases are underpowered because of the difficulty of recruiting adequate numbers of subjects. We propose a clinical trial design with improved statistical power compared to the traditional randomized trial for use in clinical trials of rare diseases. The three-stage clinical trial design consists of an initial randomized placebo-controlled stage, a randomized withdrawal stage for subjects who responded, and a third randomized stage for placebo non-responders who subsequently respond to treatment. Test level and power were assessed by computer-intensive exact calculations. The three-stage clinical trial design was found to be consistently superior to the traditional randomized trial design in all cases examined, with sample sizes typically reduced by 20 per cent to 30 per cent while maintaining comparable power. When a treatment clearly superior to placebo was considered, our design reached a power of 75 per cent with a sample of 21 patients compared with the 52 needed to attain this power when only a randomized controlled trial was used. In situations where patient numbers are limited, a three-stage clinical trial design may be a more powerful design than the traditional randomized trial for detecting clinical benefits.
    Statistics in Medicine 10/2001; 20(20):3009-21. DOI:10.1002/sim.980 · 2.04 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Publisher’s description: Drug development is the process of finding and producing therapeutically useful pharmaceuticals, turning them into safe and effective medicine, and producing reliable information regarding the appropriate dosage and dosing intervals. With regulatory authorities demanding increasingly higher standards in such developments, statistics has become an intrinsic and critical element in the design and conduct of drug development programmes. This text presents an essential and thought provoking guide to the statistical issues and controversies involved in drug development. The second edition has been updated to include: A comprehensive coverage of the design and interpretation of clinical trials; Expanded sections on missing data, equivalence, meta-analysis and dose finding. An examination of both Bayesian and frequentist methods. A new chapter on pharmacogenomics and expanded coverage of pharmaco-epidemiology and pharmaco-economics. Coverage of the ICH guidelines, in particular ICH E9, Statistical Principles for Clinical Trials. It is hoped that the book will stimulate the dialogue between statisticians and life scientists working within the pharmaceutical industry. The accessible and wide-ranging coverage make it an essential reading for both statisticians and non-statisticians working in the pharmaceutical industry, regulatory bodies and medical research institutes. There is also much to benefit undergraduate and postgraduate students whose courses include a medical statistics component.
    01/2008: pages 405; John Wiley., ISBN: 0 471 97488 9